


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Deferiprone. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Deferiprone

Revised: December 3, 2018.

CASRN: 30652-11-0



Drug Levels and Effects

Summary of Use during Lactation

Because no information is available on the use of deferiprone during breastfeeding and it is orally absorbed, an alternate drug is preferred, especially while nursing a newborn or preterm infant. Australian guidelines recommend against breastfeeding during deferiprone treatment.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Deferoxamine, Deferasirox

References

1. Ho PJ, Tay L, Lindeman R et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. Intern Med J. 2011;41:516-24. PubMed PMID: 21615659.

Substance Identification

Substance Name

Deferiprone

CAS Registry Number

30652-11-0

Drug Class

Breast Feeding

Lactation

Chelating Agents

Iron Chelating Agents